September 2022 Issue | Blood Cancers Today

September 2022

This issue of Blood Cancers Today includes a feature on how to successfully CAR-T therapies into the management of large B-cell lymphoma, a debate on whether MRD negativity indicates a cure in patients with ALL, and more.

Viewpoints

Editor's Message

Immunotherapy Modalities Are Here to Stay

Features

News

In the Literature

Triplet Combination Demonstrates Efficacy in Patients with Myeloma

Polatuzumab Vedotin Plus Chemoimmunotherapy Can Be Cost-Effective Against Untreated DLBCL in Certain Settings

News Roundup

‘Survival Advantage’ Seen with Brentuximab Vedotin in Stage III or IV Hodgkin Lymphoma

Bacterial Infections Linked to High Mortality in Newly Diagnosed Myeloma

Second Allogeneic HSCT ‘Reasonable’ Treatment Option for Patients with Relapsed AML

PANTHER Trial Compares Pevonedistat Plus Azacitidine vs Azacitidine Alone in MDS, AML

Sorafenib and Plerixafor Plus G-CSF Mobilizes Leukemia Cells, Leads to ‘Encouraging Rates of Response’ in FLT3/ITD-Mutated AML

Study Shows Benefits of CAR T-Cell Therapy for Refractory Diffuse LBCL

No Survival Benefit From HSCT in Patients with Ph+ ALL in First Complete Molecular Remission

Regulatory Actions

European Medicines Agency Issues Positive Opinion on Orphan Drug Designation for Tamibarotene for the Treatment of MDS

FDA Agrees on Proposal for Initial Pediatric Study Plan for SGX301

FDA Approves Acalabrutinib for CLL, SLL, R/R MCL

FDA Grants Orphan Drug Designation to Investigational Small-Molecule Inhibitor DSP-5336 for AML

European Commission Approves Ibrutinib in Fixed-Duration Combination Regimen for Adult Patients with Previously Untreated CLL

Brexucabtagene Autoleucel Receives Positive Opinion From EMA for R/R ALL

EC Grants Full Marketing Authorization to Selinexor for Relapsed Myeloma

Teclistamab Receives Positive Opinion From EMA for Adults with R/R Myeloma

FDA Clears IND Application for CK0804 as Add-On Therapy to Ruxolitinib for Treatment of MF

State of the Art

Current and Emerging Treatment Regimens for Waldenström Macroglobulinemia

Editorial Board

Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine

Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center

Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center

Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch

Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer